SAGE Therapeutics Inc SAGE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:53 PM EDT
12.17quote price arrow up+0.27 (+2.25%)
Volume
427,551
52 week range
10.92 - 59.99
Loading...
  • Open11.96
  • Day High12.38
  • Day Low11.81
  • Prev Close11.90
  • 52 Week High59.99
  • 52 Week High Date06/12/23
  • 52 Week Low10.92
  • 52 Week Low Date04/17/24

Key Stats

  • Market Cap732.265M
  • Shares Out60.18M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-43.7

KEY STATS

  • Open11.96
  • Day High12.38
  • Day Low11.81
  • Prev Close11.90
  • 52 Week High59.99
  • 52 Week High Date06/12/23
  • 52 Week Low10.92
  • 52 Week Low Date04/17/24
  • Market Cap732.265M
  • Shares Out60.18M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-43.7

RATIOS/PROFITABILITY

  • EPS (TTM)-8.40
  • P/E (TTM)-1.45
  • Fwd P/E (NTM)-1.88
  • EBITDA (TTM)-507.263M
  • ROE (TTM)-54.72%
  • Revenue (TTM)91.064M
  • Gross Margin (TTM)96.49%
  • Net Margin (TTM)-552.52%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On SAGE Therapeutics Inc

 

Profile

MORE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a...
Geno Germano
Independent Chairman of the Board
Barry Greene
President, Chief Executive Officer, Director
Kimi Iguchi
Chief Financial Officer, Treasurer
Address
215 1st St
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
RGNX
Regenxbio Inc
15.80+0.36+2.33%
YMAB
Y-mAbs Therapeutics Inc
12.32+0.04+0.33%
NRIX
Nurix Therapeutics Inc
13.79+0.29+2.11%
IMTX
Immatics NV
11.00+0.17+1.57%
ZNTL
Zentalis Pharmaceuticals Inc
11.89-0.64-5.14%